A Phase 2 Randomized, Double-Blind, Placebo-Controlled, 2-Arm, Multi-Center Study Comparing Tivozanib Hydrochloride In Combination With Paclitaxel Versus Placebo In Combination With Paclitaxel in the Treatment of Subjects With Locally Recurrent and/or Metastatic Triple Negative Breast Cancer.

Trial Profile

A Phase 2 Randomized, Double-Blind, Placebo-Controlled, 2-Arm, Multi-Center Study Comparing Tivozanib Hydrochloride In Combination With Paclitaxel Versus Placebo In Combination With Paclitaxel in the Treatment of Subjects With Locally Recurrent and/or Metastatic Triple Negative Breast Cancer.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 30 Jun 2015

At a glance

  • Drugs Tivozanib (Primary) ; Paclitaxel
  • Indications Advanced breast cancer
  • Focus Therapeutic Use
  • Acronyms BATON-BC
  • Sponsors AVEO Oncology
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 30 Jan 2014 Status changed from recruiting to discontinued due to insufficient enrolment as reported in an AVEO Oncology media release.
    • 21 Aug 2013 New source identified and integrated (Memorial Sloan-Kettering Cancer Center; 13-047).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top